Characteristics and outcome of patients with second primary lung cancer
|
|
- Delphia Nicholson
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE LUNG CANCER Characteristics and outcome of patients with second primary lung cancer Niels Reinmuth 1,2, Andreas Stumpf 1, Patrick Stumpf 1, Thomas Muley 2,3, Sonja Kobinger 2,3, Hans Hoffmann 2,3, Felix J.F. Herth 2,4, Philipp A. Schnabel 2,5, Arne Warth 2,5, Helge Bischoff 1,2 and Michael Thomas 1,2 Affiliations: 1 Depts of Thoracic Oncology, Thoraxklinik, University of Heidelberg, Heidelberg, 2 Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, 3 Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, 4 Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, and 5 Institute of Pathology, University of Heidelberg, Heidelberg, Germany. Correspondence: N. Reinmuth, Lung Clinic Grosshansdorf, Department of Thoracic Oncology, Wöhrendamm 80, D Grosshansdorf, Germany. Nielsreinmuth@gmx.net ABSTRACT Patients with lung cancer are at risk of developing a second primary lung cancer (SPLC). However, the characteristics of patients at risk remain largely speculative. We reviewed 2816 lung cancer patients from our institution for the occurrence of SPLC. Any SPLC was categorised as synchronous when diagnosed within 2 years of the first primary lung cancer (FPLC) and after direct histological comparison of both tumours. All other SPLCs were considered as metachronous. 139 patients developed a second malignancy including 69 nonsmall cell lung cancer (NSCLC) and 9 small cell lung cancer. The median interval for diagnosis of metachronous SPLC (n559) after FPLC occurrence was 72 months. SPLC detected within 5 years of FPLC diagnosis had a more favourable stage distribution (p50.02). After diagnosis of SPLC, patients had a superior median overall survival compared to controls (57.7 versus 18.1 months; p,0.0001). Interestingly, comparing only stage IV NSCLC patients, a history of FPLC was also associated with a favourable survival (median 27.4 versus 8.97 months; p50.007). In summary, previous lung cancer treatment does not lead to impaired prognosis after diagnosis of SPLC. Improved surveillance programmes beyond 5 years after FPLC treatment may result in more favourable disease stages for detected Previous lung cancer treatment does not lead to impaired prognosis after diagnosis of secondary primary lung cancer Received: Feb Accepted after revision: Aug First published online: Oct Conflict of interest: None declared. Copyright ßERS Eur Respir J 2013; 42: DOI: /
2 Introduction Lung cancer remains one of the most frequent human cancers and the leading cause of cancer-related deaths in the western world [1]. Since most lung cancer patients present with advanced or metastatic disease, the overall 5-year survival rate is only 15% [1]. However, after or during treatment for lung cancer, patients may develop another malignancy, including a second primary lung cancer (SPLC). Some authors have described an increased risk of developing SPLC for lung cancer patients which has been attributed largely to the risks of tobacco consumption [2 4]. The incidence of SPLC has been reported at 1 2% per patient-year [5, 6]. Still, relatively few data have been published about this selected group of patients with sometimes conflicting results. Most of these data have been generated in the 20th century and included low patient numbers, derived either from multiple institutions or over a long time period, that may have rendered conclusions difficult as a result of varying diagnostic procedures and therapeutic developments. Moreover, data regarding clinical characteristics is lacking for patients with first primary lung cancer (FPLC) who might be at risk for developing SPLC. Current surveillance programmes of lung cancer patients do not specifically address the risk of developing a second malignancy [7, 8]. Hence, we conducted a retrospective analysis of SPLC patients diagnosed and treated in our institution within a defined and recent time interval. Methods Patients Retrospectively, we reviewed all lung cancer patients who were treated in our institution between January 1, 2004, and December 31, 2006 using the hospital information system and medical records. In addition, and upon approval by the local ethics committee, patients or their treating physicians were contacted, and the follow-up statuses were completed. The staging of lung cancer was performed according to the sixth edition of TNM (tumour, node, metastasis) criteria; however, all data was also analysed using the seventh TNM classification. Lung cancer patients without a second malignancy served as the control group. The smoking status was assessed at diagnosis of the SPLC. In agreement with other studies, former smoking status was defined for patients with a nicotine cessation of at least 6 months [9, 10]. Patients with a total consumption of less than 100 cigarettes were classified as never-smokers. Definition of a second primary lung tumour To identify two lung primary tumours as independent, the criteria established by MARTINI and MELAMED [11] and ANTAKLI et al. [6] were used. Briefly, tumours with the same histology must have either an interval of at least 2 years, originate from carcinoma in situ or be located in different lungs, lobes or segments without common lymphatics and without distant metastases to be considered as independent primaries. In a similar manner to previous studies, synchronous SPLC was identified if an independent SPLC was evident within 2 years after diagnosis of the FPLC [5, 11]. For synchronous cancers with similar histology, the occurrence of an independent SPLC was confirmed by an independent pathologist after histological TABLE 1 Locations of a second malignancy after diagnosis of lung cancer Location of second malignancy First primary lung cancer NSCLC SCLC Total Another lung cancer 69 (55.6) 9 (60.0) 78 (56.2) Head neck 8 (6.5) 2 (13.3) 10 (7.2) Kidney 2 (1.6) 2 (13.3) 4 (2.9) Bladder 9 (7.4) 0 9 (6.5) Oesophagus 1 (0.8) 0 1 (0.7) Colon 6 (4.8) 1 (6.7) 7 (5.0) Rectum 4 (3.2) 0 4 (2.9) Breast 5 (4.0) 1 (6.7) 6 (4.3) Ovary 1 (0.8) 0 1 (0.7) Liver 4 (3.2) 0 4 (2.9) Pancreas 2 (1.6) 0 2 (1.4) Adrenal gland 1 (0.8) 0 1 (0.7) Prostate 8 (6.5) 0 8 (5.8) Melanoma 2 (1.6) 0 2 (1.4) Skin cancer other than melanoma 2 (1.6) 0 2 (1.4) Total 124 (100) 15 (100) 139 (100) Data are presented as n (%). NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer. DOI: /
3 comparison of both tumours. An independent SPLC discovered later than 2 years was labelled metachronous. Follow-up after therapy of FPLC All patients entered a follow-up programme with 3-monthly visits for the first 2 years, 6-monthly visits after 2 5 years and yearly visits thereafter [7]. In addition, SCLC patients were seen every 2 months for the first year. All follow-up visits included physical examination, lung function tests and a chest radiograph. In surgically treated patients, a computed tomography scan was performed every 6 months for the first 2 years. Statistical analysis The census date was fixed after a minimum period of follow-up of at least 46 months for each patient. As end-points, we used the date of death or survival at the last documented contact with the patient. Collectively, a total of 6326 person-years (4638 person-years for males and 1688 person-years for females) of observation were noted. Patients who died of causes other than lung cancer were censored. Quantitative variables were summarised with their mean or median. Two-sided analysis of variance and the Chi-squared test were performed where appropriate. Survival curves of the different subgroups are presented according to the Kaplan Meier method. Throughout, p,0.05 was considered to be statistically significant. Results A total of 139 patients with a second malignancy after diagnosis of lung cancer were identified (table 1) resulting in a prevalence of 2.41% per patient-year. Among these, 78 patients developed a SPLC (prevalence 1.33% per patient-year; 65 nonsmall cell lung cancer (NSCLC) and 13 small cell lung cancer (SCLC); table 2). In 19 patients, SPLCs were diagnosed synchronously. For metachronous SPLCs, the median (range) interval between diagnosis of FPLC and SPLC was 72 ( ) months with most SPLC diagnosed after 5 years of FPLC diagnosis. In contrast, a group of 2675 lung cancer patients developed no further malignancy and served as the control group. While the current health status could not be updated TABLE 2 Patient characteristics Characteristics Patients with SPLC Control group Patients Age at time of diagnosis of FPLC Median age years Age range years Age distribution f29 years years years years years years o80 years 0 97 Sex Male Female Smoking status Current smoker 47 (61.8) 1473 (74.0) Former 18 (23.7) 372 (18.7) Never 11 (14.5) 146 (7.3) Unknown Median pack-years Interval FPLC SPLC,1 month months 2 6 months 1 year years years years years 17 Data are presented as n or n (%), unless otherwise stated. FPLC: first primary lung cancer; SPLC: second primary lung cancer DOI: /
4 for 471 patients (11 patients with SPLC; 460 patients in the control group) the mean follow-up was 26.1 months for all patients (median 15.4 months) and 43.9 months for surviving patients (median 43.6 months). Characteristics of FPLC Of the 78 patients who later developed a SPLC, 69 and nine patients had a previous NSCLC and SCLC, respectively. Compared to controls, the median age of patients with FPLC was younger (58 versus 64 years in controls). Interestingly, while significantly more FPLC patients were former and never-smokers (p,0.05), those patients who did smoke had a higher median cigarette consumption (55 versus 47.5 packyears; p,0.01). Since most FPLCs were diagnosed in early stages (table 3), most patients underwent surgical resection (86%) or radiation therapy of FPLC (26%). No FPLC was treated with chemotherapy alone. All three first primary NSCLC patients with stage IV disease had lung metastases (ipsilateral in two patients; contralateral in one patient) as the only metastasis location and underwent complete resection of both the primary tumour and metastases, followed by chemotherapy in two cases. One SCLC patient with brain metastasis, that was treated with chemotherapy and cerebral radiation, developed a SPLC after 7 years. Characteristics of SPLC At diagnosis of SPLC (65 NSCLC, 13 SCLC), the median (range) age was 64 (45 81) years which was similar to controls. NSCLC and SCLC as metachronous SPLC were diagnosed after a median interval of 77 ( ) and 67 (29 226) months after diagnosis of FPLC, respectively. There were no significant differences between synchronous and metachronous SPLC. All but one SCLC developed as metachronous cancer. No patient with SCLC as FPLC developed another SCLC as a SPLC. In cases of adenocarcinoma or squamous cell carcinoma as FLPC, 65% and 46% of patients also had a similar histology as SPLC, respectively (table 4). Similar to FPLC, most SPLC were diagnosed as stage I (51.3%) and stage II (11.5%) disease which was independent from the stage of FPLC. Interestingly, SPLC disease detected within or after 5 years after TABLE 3 Disease and treatment characteristics FPLC SPLC Control group Histology NSCLC 69 (88.5) 65 (11.5) 2188 (81.8) Adenocarcinoma Squamous cell carcinoma Large cell carcinoma NSCLC, not specified SCLC 9 (11.5) 13 (16.7) 487 (18.2) Stage distribution NSCLC I 40 (57.9) 38 (58.5) 544 (24.9) II 14 (20.3) 6 (9.2) 166 (7.6) III 12 (17.3) 11 (16.9) 733 (33.5) IV 3 (4.3) 10 (15.4) 745 (34.0) Stage distribution SCLC I 1 (11.1) 2 (15.4) 36 (7.4) II 0 3 (23.1) 11 (2.3) III 7 (78,8) 3 (23.1) 226 (46.4) IV 1 (11.1) 5 (38.4) 214 (43.9) Initial treatment Surgery only Radiation therapy only Chemotherapy only Combination therapy Surgery and chemotherapy Surgery and radiation therapy Radiation therapy and chemotherapy All modalities No treatment Data are presented as n or n (%). FPLC: first primary lung cancer; SPLC: second primary lung cancer; NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer. DOI: /
5 TABLE 4 Development of second primary lung cancer (SPLC) with regard to the histology of the first primary lung cancer (FPLC) FPLC SPLC Histology n Histology n Adenocarcinoma 31 Adenocarcinoma 20 Squamous cell carcinoma 7 Large cell carcinoma 2 SCLC 2 Squamous cell carcinoma 28 Adenocarcinoma 6 Squamous cell carcinoma 13 Large cell carcinoma 0 SCLC 9 Large cell carcinoma 8 Adenocarcinoma 4 Squamous cell carcinoma 2 Large cell carcinoma 0 SCLC 2 SCLC 9 Adenocarcinoma 2 Squamous cell carcinoma 5 Large cell carcinoma 2 SCLC 0 NSCLC, NOS 2 Adenocarcinoma 1 Squamous cell carcinoma 1 Large cell carcinoma 0 SCLC 0 Total SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; NOS: not otherwise specified. diagnosis of FPLC had a different stage distribution (p50.02; table 5). While SPLC was detected as stage I disease in 65% of cases when diagnosed within 5 years of FPLC detection, this stage was only present in 34% when diagnosed after 5 years of FPLC. In contrast, SPLC was diagnosed as stage III/IV disease in 30% and 46%, respectively, when detected within or after 5 years of FPLC. The most frequent localisation of SPLC was the left upper lobe (35.1%) while FPLC was most often found in the right upper lobe (47.4%). In comparison, lung cancers of the control group were located in the left and right upper lobes in 26.1% and 29.5%, respectively. Compared to FPLC, stage I and II SPLC underwent less frequent surgical resection (78% versus 98%) but were treated more often with radiotherapy (29% versus 7%). Of all stage IV SPLC patients, two patients had single lung metastases that were completely resected with the primary tumour. Another patient had brain metastases and received radiation of both the thoracic tumour and brain metastases. Two stage IV patients could not be offered treatment due to poor performance status. All other stage IV patients (n510) were treated with systemic chemotherapy alone. Survival SPLC patients had a median overall survival of 12.6 years (95% CI months) and 4.8 years (95% CI months) determined from the date of diagnosis of FPLC and SPLC, respectively. In comparison, the control group had a median survival of 1.5 years ( months; p,0.0001). At the end of data bank closure, 46 (59%) patients with SPLC were still alive including 11 patients who were lost to follow-up. Interestingly, the survival benefit for SPLC compared to controls held true for smokers (median 57.7 versus 18.1 months; p50.01) but not for former (p50.11) or never smokers (p50.14). Patients with synchronous SPLC had a better overall survival after diagnosis of SPLC compared to metachronous SPLC patients (median not reached versus 42.6 months; p,0.05). While the survival of SPLC patients with SCLC was not significantly different from controls (median 16.3 versus 13.3 months; p50.64), patients with NSCLC as SPLC lived more than four times longer after SPLC diagnosis than NSCLC control patients (median not reached versus 19.8 months, p,0.0001; fig. 1). Comparing NSCLC patients with similar disease stages, a history of FPLC was associated with superior survival for patients with stage IIIA (median versus 26.5 months; p50.001) and stage IV disease (median 27.4 versus 8.97 months; p50.006; fig. 2). When all cancers were reclassified using the seventh 1672 DOI: /
6 TABLE 5 Stage distribution of second primary lung cancer depending on the time interval after diagnosis of first primary lung cancer Stage Interval,5 years Interval.5 years I 28 (65) 12 (34) II 2 (5) 7 (20) III 6 (14) 8 (23) IV 7 (16) 8 (23) Data are presented as n (%). TNM classification, the difference in overall survival for SPLC NSCLC patients versus controls held true (median not reached versus 8.8 months; p50.007). However, SPLC patients with stage IV disease (both NSCLC and SCLC) receiving only chemotherapy were not significantly different to the respective control patients (10 versus 650 patients; p50.14). Patients with additional malignancies Besides developing a SPLC, eight patients (10.2%; six male, two female) developed a third malignancy after the FPLC including a third primary lung cancer (two patients), melanoma (two patients), prostate cancer and sarcoma (one patient each). In two cases, the origin of the third malignancy remained unknown. At the end of data bank closure, five of these patients were still alive. Discussion To our knowledge, this report reflects on the largest number of patients with SPLC from a single institution with uniform staging and diagnosis criteria. The prevalence of a second malignancy in all lung cancer patients investigated in our study was 2.41% per patient-year, which was somewhat higher compared to data from a large survey including cancer patients (5799 with lung cancer) from from a Japanese institution [12]. In this study, the risk for second malignancy was 0.008% and 1.87% per patientyear for all cancer patients or lung cancer patients only, respectively. Compared to expected values in the general population, the risk of developing a SPLC was 4.6 and 7.8 times higher for male and female patients with lung cancer, respectively. Since 1962, progress in diagnostic and therapeutic options such as the introduction of adjuvant chemotherapy after complete resection has influenced the general outcome of lung cancer with a possible impact on the occurrence of second malignancies. In our study with 2004 as the start entry for collecting data, second primaries were most often located in the lung (55% as compared to only 45% for all other organ cancers combined). In comparison, only 11.04% of all tumour patients being diagnosed in Germany in 2006 had lung cancer [13]. The risk of 1.33% per patient-year for developing a SPLC is in congruence with the estimate of 1 2% per year after the diagnosis of FPLC in other studies [4, 5]. Some authors described a higher risk of SCLC patients for developing a SPLC [2, 14] as compared to the risk for SPLC after NSCLC [5]. However, we did not detect significant differences in this regard. 100 Patients with SPLC Control group 80 FIGURE 1 Survival of nonsmall cell lung cancer (NSCLC) patients with or without a second primary lung cancer (SPLC). NSCLC patients with a history of a previous primary lung cancer had a significantly superior survival compared to control patients without previous malignancy and diagnosed in the same time interval (p,0.0001). Survival % Years DOI: /
7 Patients with SPLC Control group Survival % Years FIGURE 2 Survival of stage IV nonsmall cell lung cancer (NSCLC) patients with and without a second primary lung cancer (SPLC). Patients with SPLC (n510) had a significantly improved survival after diagnosis of the SPLC compared to controls (n5745; p50.006). Patients with SPLC and a smoking history had a significantly higher cigarette consumption compared to controls, which is similar to previous data [15]. In accordance with other data, the predominant histology of SPLC after SCLC was squamous cell carcinoma [14, 16] which may also indicate high nicotine consumption as a risk factor. Collectively, high nicotine consumption remains a major risk factor especially in those patients who continue cigarette smoking after diagnosis of lung cancer [17, 18]. There is an ongoing discussion on the arbitrary distinction between synchronous and metachronous SPLC [19, 20]. In our study, 24% of SPLCs were diagnosed as synchronous tumours. We followed most previous studies in using the definition by MARTINI and MELAMED [11]. Moreover, in cases of similar histology, histological sections from both FPLC and SPLC were compared. This approach may have contributed to a lower incidence of synchronous SPLC compared to others who described approximately one third of all SPLC patients as synchronous [21, 22]. However, the histological pattern may have been changed in relapse tumours. As a perspective, a better identification of the independence of lung primaries may involve molecular assessments such as gene array analyses or patterns of loss of heterozygosity. In a limited number of synchronous and metachronous pulmonary tumours, assessment of loss of heterozygosity patterns demonstrated that the previous classification of synchronous and metachronous tumours based on the criteria suggested by MARTINI and MELAMED [11] held true for most, but not all cases [23]. Most metachronous SPLCs were diagnosed 5 years after diagnosis of the FPLC which is somewhat similar to two retrospective studies on surgical patients developing metachronous SPLC [24 26]. Interestingly, and previously unaddressed, SPLC disease was detected in a more advanced stage when diagnosed more than 5 years after diagnosis of FPLC compared to SPLC patients with a shorter interval. This may have been the consequence of the extension of follow-up visits to a yearly schedule. However, whether a more frequent surveillance programme after 5 years may have led to diagnosis of more SPLC in earlier stages remains speculative and would need to be addressed in larger clinical studies [5]. The 5-year survival rate of 44% of all SPLC patients in our study is congruent with data from 41 resected patients with metachronous lung cancer [26]. Some studies on patients with surgically treated metachronous SPLC report somewhat lower outcomes despite recruiting only patients with early tumour stages (26% 33%) [27, 28]. The finding of earlier studies that support a worse prognosis for patients with synchronous lung tumours compared to metachronous tumours could not be confirmed in our study [6, 26]. Compared to our control group, patients lived significantly longer after SPLC diagnosis, an effect that, at least in part, may be explained by positive patient selection. SPLC patients had more favourable disease stages and were more often never or former smokers. Moreover, one should also consider competing risks caused by major comorbidities, in particular pulmonary and cardiovascular diseases. While this data could not be evaluated for the current manuscript, future evaluations should address this issue as well as possible long-term side-effects caused by the previous treatments. Comparing the outcome of similar disease stages between NSCLC patients with and without SPLC, stage IV SPLC patients had a significantly better overall survival that held true even after reanalysis using the seventh TNM classification for all lung cancers. Comparing only stage IV NSCLC patients receiving exclusively chemotherapy, the superior outcome failed significance possibly due to low patient numbers. In contrast, the survival of patients after diagnosis of SCLC as SPLC was not different to control patients. Again, the case numbers were low. As a hypothesis, metastatic disease may rather reflect the biology of the disease 1674 DOI: /
8 compared to limited stages treated with surgery or radiation. Since various epigenetic and genetic alterations may modify lung cancer risk and development, the better overall survival of patients with SPLC may indicate a distinct epigenetic profile [29, 30]. Reflecting the opportunity of a favourable outcome, as shown in the recent analysis, SPLC should be attributed to an as best treatment approach. As examples of such an approach selected stage IV NSCLC patients with solitary adrenal gland, brain or contralateral lung metastasis did benefit from complete resection of both primary lung tumour and metastasis resulting in a favourable outcome [31 33]. Moreover, according to the revised staging system, patients with ipsilateral lung metastasis are now classified as having T4 tumours [34]. In summary, our data suggest that lung cancer patients should be closely monitored after treatment with possibly shorter intervals beyond 5 years. Patients with multiple or recurrent thoracic tumours should be carefully staged and, if justifiable depending on expected risks for the patient, be re-biopsied in order to distinguish SPLC from recurrent FPLC. The prognosis of SPLC patients does not seem to be worse compared to other patients with lung cancer and may even be superior in certain circumstances [35]. References 1 Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin 2008; 58: Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997; 89: van Bodegom PC, Wagenaar SS, Corrin B, et al. Second primary lung cancer: importance of long term follow up. Thorax 1989; 44: Levi F, Randimbison L, Te VC, et al. Second primary cancers in patients with lung carcinoma. Cancer 1999; 86: Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90: Antakli T, Schaefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg 1995; 59: Goeckenjan G, Sitter H, Thomas M, et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2010; 65: Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: Coultas DB, Howard CA, Peake GT, et al. Discrepancies between self-reported and validated cigarette smoking in a community survey of New Mexico Hispanics. Am Rev Respir Dis 1988; 137: Barbone F, Bovenzi M, Cavallieri F, et al. Cigarette smoking and histologic type of lung cancer in men. Chest 1997; 112: Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70: Kobayashi Y, Arimoto H, Watanabe S. Occurrence of multiple primary cancer at the National Cancer Center Hospital, Jpn J Clin Oncol 1991; 21: Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.v. Krebs in Deutschland 2005/2006. Häufigkeiten und Trends [Cancer in Germany 2005/2006]. Berlin, Robert Koch-Institut, Available from: 14 Johnson BE, Cortazar P, Chute JP. Second lung cancers in patients successfully treated for lung cancer. Semin Oncol 1997; 24: Sugimura H, Watanabe S, Tsugane S, et al. Case-control study on histologically determined multiple primary lung cancer. J Natl Cancer Inst 1987; 79: Smythe WR, Estrera AL, Swisher SG, et al. Surgical resection of non-small cell carcinoma after treatment for small cell carcinoma. Ann Thorac Surg 2001; 71: Gritz ER, St Jeor ST, Bennett G, et al. National working conference on smoking and body weight. Task Force 3: implications with respect to intervention and prevention. Health Psychol 1992; 11: Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: Ribet M, Dambron P. Multiple primary lung cancers. Eur J Cardiothorac Surg 1995; 9: Paci M, Sgarbi G, Annessi V, et al. Multiple primary lung cancers: comment on current opinions. Lung Cancer 2003; 39: Deschamps C, Pairolero PC, Trastek VF, et al. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg 1990; 99: Riquet M, Cazes A, Pfeuty K, et al. Multiple lung cancers prognosis: what about histology? Ann Thorac Surg 2008; 86: Huang J, Behrens C, Wistuba I, et al. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol 2001; 5: Doddoli C, Thomas P, Ghez O, et al. Surgical management of metachronous bronchial carcinoma. Eur J Cardiothorac Surg 2001; 19: Lee BE, Port JL, Stiles BM, et al. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg 2009; 88: Aziz TM, Saad RA, Glasser J, et al. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg 2002; 21: van Rens MT, Zanen P, de la Riviere AB, et al. Survival after resection of metachronous non-small cell lung cancer in 127 patients. Ann Thorac Surg 2001; 71: Faber LP. Resection for second and third primary lung cancer. Semin Surg Oncol 1993; 9: DOI: /
9 29 Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008; 123: Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011; 183: Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26: Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg 2010; 37: Melloni G, Bandiera A, Gregorc V, et al. Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience. J Cardiovasc Surg (Torino) 2011; 52: Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming 7th edn of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. Lung Cancer 2001; 34: DOI: /
Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationThe distinction of synchronous primary lung cancers
ORIGINAL ARTICLE Predictors of Outcomes after Surgical Treatment of Synchronous Primary Lung Cancers David J. Finley, MD,* Akihiko Yoshizawa, MD, William Travis, MD, Qin Zhou, MA, Venkatraman E. Seshan,
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationSurgical Treatment of Metachronous Nonsmall Cell Lung Cancer
Original Article Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Shuji Haraguchi, MD, 1,2 Kiyoshi Koizumi, MD, 1,2 Tomomi Hirata, MD, 1,2 Kyoji Hirai, MD, 1,2 Iwao Mikami, MD, 1,2 Hirotoshi
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationDiagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD November 18, 2017 Disclosures I do not have a financial interest/arrangement or affiliation with one or more organizations
More informationORIGINAL ARTICLE. Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer
ORIGINAL ARTICLE Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer Choonhee Son 1, Soo Keol Lee 1, Phil Jo Choi 2, Mee Sook Roh 3 Departments of 1 Internal
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationIt is well established that patients undergoing treatment
Surgical Resection of Non Small Cell Carcinoma After Treatment for Small Cell Carcinoma W. Roy Smythe, MD, Anthony L. Estrera, MD, Stephen G. Swisher, MD, Kelly W. Merriman, MPH, Garrett L. Walsh, MD,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationPAPER. See Invited Critique at end of article
PAPER Systematic Postoperative Radiologic Follow-up in Patients With Non Small Cell Lung Cancer for Detecting Second Primary Lung Cancer in Stage IA Jeffrey P. Lamont, MD; James T. Kakuda, MD; David Smith,
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe Risk of Second Primary Tumors After Resection of Stage I Nonsmall Cell Lung Cancer
The Risk of Second Primary Tumors After Resection of Stage I Nonsmall Cell Lung Cancer David Rice, MB, BCh, Hyung-Woo Kim, MS, Anita Sabichi, MD, Scott Lippman, MD, J. Jack Lee, PhD, Brendell Williams,
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationStage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis
Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationLung cancer is the leading cause of cancerrelated. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Eur Respir J 2012; 39: 1437 1442 DOI: 10.1183/09031936.00105911 CopyrightßERS 2012 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Arne Warth*,e, Stephan Macher-Goeppinger*,#,e,
More informationRevisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data
CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationLung Cancer as a Second Primary Malignancy: Increasing Prevalence and Its Influence on Survival
Ann Surg Oncol (2009) 16:1033 1038 DOI 10.1245/s10434-008-0296-1 ORIGINAL ARTICLE THORACIC ONCOLOGY Lung Cancer as a Second Primary Malignancy: Increasing Prevalence and Its Influence on Survival Silvia
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationAttending Physician Statement- Cancer or Carcinoma in-situ
Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Cancer or Carcinoma in-situ.
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationSurgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital
Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationT he increasing incidence and poor survival of patients
710 LUNG CANCER Survival after resection for primary lung cancer: a population based study of 3211 resected patients T-E Strand, H Rostad, B Møller, J Norstein... See end of article for authors affiliations...
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationLung cancer is now a major cause of death in developed
Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,
More informationTreatment of Multiple Lung Tumors
VUmc SABR Symposium 2017 Treatment of Multiple Lung Tumors Indications and Dosimetric Considerations Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health Sciences Centre Clinician-Scientist,
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationChanges in TNM-classification 7 th edition T T1 2 cm T1a
Introduction 1 Chapter 1 Introduction 9 Currently, cancer is the second leading cause of death in Europe 1. Globally, lung cancer is by far the most common cause of cancer-related deaths, and is by itself
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationclinical investigations The Experience of an Academic Multidisciplinary Program
clinical investigations Lung Cancer in Patients < 50 Years of Age* The Experience of an Academic Multidisciplinary Program Shirish M. Gadgeel, MD; Sakkaraiappan Ramalingam, MD; Glenn Cummings, PhD; Michael
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationSmall-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationClinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during
Original Article Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011 2015 Pingli Wang 1 *, Jixia Zou 1 *, Jingni Wu 1 *, Chengyan Zhang
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationEditorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD
Accepted Manuscript Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD PII: S0022-5223(18)33135-0 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.036
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationOral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment
Oral Cavity 1. Introduction 1.1 General Information and Aetiology The oral cavity extends from the lips to the palatoglossal folds and consists of the anterior two thirds of the tongue, floor of the mouth,
More informationNonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis
1998 Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis Chaosu Hu, M.D. 1 Eric L. Chang, M.D. 2 Samuel J. Hassenbusch III, M.D., Ph.D. 3 Pamela K. Allen, Ph.D. 2 Shiao Y. Woo,
More informationKey words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery
Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc
More informationSurveillance following treatment of primary ocular melanoma
Surveillance following treatment of primary ocular melanoma Introduction 50% of UM patients relapse with predominantly liver metastases Risk of metastatic disease can be predicted relatively accurately
More informationLung cancer: the importance of seeing a respiratory physician
Eur Respir J 2003; 21: 606 610 DOI: 10.1183/09031936.03.00060803 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Lung cancer: the importance
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More information